Zhengye Biotechnology Holding Ltd.
ZYBT
Zhengye Biotechnology Holding Ltd. Class A Ordinary Shares represents the equity of Zhengye Biotechnology Holding Limited, a veterinary vaccine manufacturer focused on research, development, manufacturing, and sales of vaccines for livestock and other animals. The company’s product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs, supporting disease prevention across animal health markets in China. Its business is centered on serving veterinary and agricultural needs through a range of monovalent, polyvalent, and combined vaccine offerings. Zhengye Biotechnology Holding Ltd. operates in the biotechnology and health technology sectors, where it plays a role in supplying immunization products used by veterinarians, farms, and livestock producers. The Class A Ordinary Shares are part of the company’s dual-class share structure and reflect its ordinary equity interests.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥116M
▼ -37.6% YoY
Net Income (TTM)
-¥83M
▼ -715.9% YoY
Op. Margin
-58.66%
▼ -67.9pp YoY
ROIC
-13.14%
▼ -16.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
¥703K
▼ -94.7% YoY
Op. Cash Flow (TTM)
¥13M
▼ -67.5% YoY
Net Debt
¥23M
Cash & Equiv.
¥52M
3Y CAGR: -23.5%
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with ZYBT
Zhengye Biotechnology Holding (ZYBT) in four numbers
Questions about Zhengye Biotechnology Holding
Is Zhengye Biotechnology Holding (ZYBT) overvalued?
At $1.38, Zhengye Biotechnology Holding's price is 47% above the $0.94 a share fair value that Intrinsiqq's calculator gets from its revenue. It trades at 617.68 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Zhengye Biotechnology Holding's fair value?
Intrinsiqq's calculator puts Zhengye Biotechnology Holding's fair value at $0.94 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 4.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.71. Every input can be changed on the Intrinsic Value tab.
Is Zhengye Biotechnology Holding a high-quality business?
Zhengye Biotechnology Holding scores 9 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from company filings. Its best check is share count change at 3.3%, and its weakest is return on capital at -13.1%. The Quality tab shows every check against its target.
Does Zhengye Biotechnology Holding (ZYBT) pay a dividend?
No. Zhengye Biotechnology Holding (ZYBT) paid CNY 0.34 per share in fiscal 2024 and has paid nothing in the last twelve months. The Dividends tab has the full payment history.
Source: company filings. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ZYBT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.